In China, For Global

An innovative and globally competitive

biopharmaceutical company with a whole-industry-chain layout.

In China, For Global

An innovative and globally competitive

biopharmaceutical company with a whole-industry-chain layout.

Original Innovation, Science Oriented

Globally-integrated R&D process

Technology system encompassing the entire lifecycle of antibodies

Innovation-driven Biopharma

China’s leading innovative biopharmaceutical company

Established in December, 2012

Therapeutic Area

  • Oncology

    JS001(PD-1), JS003 (PD-L1), JS004 (BTLA)

  • Autoimmune

    JS005 (IL-17A), UBP1211 (TNF-α), UBP1213 (BLyS)

  • Metabolic

    JS002 (PCSK9), JS103 (Uricase), JS008 (Undisclosed)

  • Neurological

    JS010 (CGRP)

  • Infectious

    JS016 (S protein), VV116 (RdRp), VV993 (3CL )

Therapeutic Area

  • Oncology
  • Autoimmune
  • Metabolic
  • Neurological
  • Infectious
Learn more

Our Milestones

News Center

  • Jan 29, 2023

    Junshi Biosciences Announces Approval for Marketing of VV116 in China

    >SHANGHAI, China, January 30, 2023 (GLOBE NEWSWIRE) – Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the “NMPA”) has conducted urgent review and approval under Special Examination and Approval of Drugs, and conditionally approved for marketing Deuremidevir Hydrobromide Tablets (project code: JT001/VV116, “VV116”), an oral nucleoside analog anti-SARS-CoV-2 drug, for the treatment of adult patients with mild to moderate coronavirus disease 2019 (“COVID-19”).

    View details
  • Dec 11, 2022

    Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting

    >SHANGHAI, China, December 10, 2022 (GLOBE NEWSWIRE) – Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the updated preliminary data from a Phase I study of tifcemalimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas in a poster at the 64th American Society of Hematology (ASH) Annual Meeting. Tifcemalimab is the world’s first-in-human anti-tumor anti-BTLA monoclonal antibody independently developed by the company.

    View details
  • Nov 15, 2022

    Junshi Biosciences Announces Submission of a Marketing Authorization Application to the European Medicines Agency for Toripalimab

    >SHANGHAI, China, November 15, 2022 (GLOBE NEWSWIRE) – Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the company has submitted a marketing authorization application (“MAA”) to the European Medicines Agency (“EMA”) for toripalimab. The indications requested in the MAA are:

    View details
Join us

"Provide patients with world-class, trustworthy, affordable, and innovative drugs"

View details